Objectives/Background: This study aims to differentiate neuro-psychiatric symptoms from aspects, according to the 2018''NIA-AA Research Framework'', 4, 4''-diaminodiphenylsulfone (DDS, Dides) as a competitor of neuroinplasma islands. We investigated Alzheimer''s disease (AD) patients who were treated with Method: In the Seoul study, ICD-9 and 10 codes were used by analyzing the effects of AD and anti-AD drugs (AAD) in the EDI database of Sorokdo National Hospital stored from January 2005 to June 2020 according to AD diagnosis criteria. I searched. A new biomarker (D) was used to manage AD symptoms and neuropsychiatric symptoms caused by AAD to classify numerical clinical staging. We report cases related to cerebral infarction and DDS as a neuroinplasma island competitor in a Seoul study. Results: DDS was a competitor to Neuroinplasma Island when comparing the proportion of AD to those who prescribed or did not prescribe DDS. By introducing (D), AD progress was monitored through NCS staging. AAD or neuropathology symptoms were distinguished and treated with DDS. AD can be exacerbated by AAD and can be restored to mild cognitive impairment by DDS. In a study in Seoul, we clinically confirmed the role of DDS as a neuroinplasma island competitor before and after a cerebral infarction. CONCLUSION: DDS is responsible for blocking normal/abnormal ubiquitination by RBS splitting, NLRP3 inflammasome formation, cascade of Higgins, and iron-rich ferromagnetic nanoparticles. AD can be prevented and treated with DDS through biomarker (D). The treatment of neuroinplasma islands as a preventive and therapeutic method for AD is proven through Numeric clinical staging (NCS).목표 / 배경 :이 연구는 신경-정신과 증상을 측면과 구별하기 위해 2018 'NIA-AA 연구 프레임 워크'에 따라 뉴로인플라마섬 경쟁자로서 4, 4'- 디아미노디 페닐설폰(DDS, 디디에스)으로 치료받은 알츠하이머병(AD) 환자를 조사했습니다. 방법 : 서울 연구에서는 AD 진단 기준에 따라 2005 년 1 월부터 2020 년 6 월까지 보관된 소록도 국립병원 EDI 데이터베이스의 AD와 항AD약물(AAD)의 효과를 분석하여 ICD-9와 10 개의 코드를 이용하여 검색 하였습니다. 새로운 바이오마커 (D)를 사용하여 AAD로 인한 AD 증상과 신경정신병
